Follow-Up on the Use of Machine Learning in Clinical Quality Assurance: Can We Detect Adverse Event Under-Reporting in Oncology Trials?

Timothé Ménard (), Björn Koneswarakantha, Donato Rolo, Yves Barmaz, Leszek Popko and Rich Bowling
Additional contact information
Timothé Ménard: F. Hoffmann-La Roche
Björn Koneswarakantha: F. Hoffmann-La Roche
Donato Rolo: Roche Products Limited
Yves Barmaz: F. Hoffmann-La Roche
Leszek Popko: F. Hoffmann-La Roche
Rich Bowling: Genentech - A Member of the Roche group

Drug Safety, 2020, vol. 43, issue 3, No 10, 295-296

Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
http://link.springer.com/10.1007/s40264-019-00894-3 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:43:y:2020:i:3:d:10.1007_s40264-019-00894-3

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-019-00894-3

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().